The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome

Korea University Anam Hospital40 enrolled

Overview

Pioglitazone and rosiglitazone are used in the treatment of diabetic patients. Thiazolidinediones increase insulin sensitivity and show favorable effect blood glucose levels and lipid profiles. The effect of these two different thiazolidinediones on atherosclerotic and inflammatory markers has not been compared in prospective manner. The purpose of this prospective, randomized, open-label, crossover trial is to compare the effect of pioglitazone and rosiglitazone on atherosclerotic and inflammatory markers in patients with metabolic syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metabolic Syndrome

Interventions

Pioglitazone, Rosiglitazone

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with at least 3 metabolic syndrome criteria of Asian-Pacific ATP III guideline: fasting blood glucose ≥ 110 mg/dl, systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, triglyceride ≥ 150 mg/dl, HDL-cholesterol \< 40 mg/dl for men and \< 50 mg/dl for women. * Age: 18 years and above Exclusion Criteria: * Hypertensive patients with the use of ACE inhibitor or ARB * Hyperlipidemic patients with the use of statin or fenofibrate * Patients with any contraindications to the treatment of thiazolidinediones * Pregnant or lactating patients * Chronic alcohol or drug abuse * Hepatic dysfunction * Renal dysfunction * Heart failure (EF \< 50%) * Expected life expectancy of \< 1 year

Outcomes

Primary Outcomes

The effect on flow-mediated dilation (FMD) and pulse wave velocity (PWV)

Secondary Outcomes

The effect of atherosclerotic and inflammatory markers such as adiponectin, IL-6, TNF-α, hsCRP.